These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Policy decision-making under scientific uncertainty: radiological risk assessment and the role of expert advisory groups. Mossman KL. Health Phys; 2009 Aug; 97(2):101-6. PubMed ID: 19590269 [Abstract] [Full Text] [Related]
26. Update of potency factors for asbestos-related lung cancer and mesothelioma. Berman DW, Crump KS. Crit Rev Toxicol; 2008 Aug; 38 Suppl 1():1-47. PubMed ID: 18671157 [Abstract] [Full Text] [Related]
27. Identifying childhood age groups for exposure assessments and monitoring. Firestone M, Moya J, Cohen-Hubal E, Zartarian V, Xue J. Risk Anal; 2007 Jun; 27(3):701-14. PubMed ID: 17640217 [Abstract] [Full Text] [Related]
31. Analysis: Secretary's Advisory Committee on Genetics, Health, and Society Report falls short. Klein RD. Hum Pathol; 2009 Feb; 40(2):147-55. PubMed ID: 19084265 [Abstract] [Full Text] [Related]
32. [Procedures and methods of benefit assessments for medicines in Germany]. Bekkering GE, Kleijnen J. Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813 [Abstract] [Full Text] [Related]
34. Endocrine disruption in the context of life cycles: perception and transduction of environmental cues. Wingfield JC, Mukai M. Gen Comp Endocrinol; 2009 Sep 01; 163(1-2):92-6. PubMed ID: 19416728 [Abstract] [Full Text] [Related]
35. Overview of endocrine disruptor research activity in the United States. Kavlock RJ. Chemosphere; 1999 Oct 01; 39(8):1227-36. PubMed ID: 10467717 [Abstract] [Full Text] [Related]
36. Immunotoxicity evaluation by immune function tests: focus on the T-dependent antibody response (TDAR) [Overview of a Workshop Session at the 45th Annual Meeting of the Society of Toxicology (SOT) March 5-9, 2006 San Diego, CA]. Herzyk DJ, Holsapple M. J Immunotoxicol; 2007 Apr 01; 4(2):143-7. PubMed ID: 18958722 [Abstract] [Full Text] [Related]